Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 14

1.

Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER.

Kaplan SA, Cardozo L, Herschorn S, Grenabo L, Carlsson M, Arumi D, Crook TJ, Whelan L, Scholfield D, Ntanios F; Assessment of Fesoterodine after Tolterodine ER (AFTER) Study Group.

Int J Clin Pract. 2014 Sep;68(9):1065-73. doi: 10.1111/ijcp.12464. Epub 2014 Jun 4.

PMID:
24898471
[PubMed - in process]
2.

An observational study of patient satisfaction with fesoterodine in the treatment of overactive bladder: effects of additional educational material.

Schneider T, Arumi D, Crook TJ, Sun F, Michel MC.

Int J Clin Pract. 2014 Sep;68(9):1074-80. doi: 10.1111/ijcp.12450. Epub 2014 May 5.

PMID:
24797765
[PubMed - in process]
3.

Flexible dosing with fesoterodine 4 and 8 mg: a systematic review of data from clinical trials.

Wyndaele JJ, Schneider T, MacDiarmid S, Scholfield D, Arumi D.

Int J Clin Pract. 2014 Jul;68(7):830-40. doi: 10.1111/ijcp.12425. Epub 2014 Apr 22.

PMID:
24754814
[PubMed - in process]
Free Article
4.

[Psychometric validation of the OAB-V8 and OAB-V3 scales for the screening of patients with probable overactive bladder in the Spanish population.]

Brenes FJ, Angulo JC, Ochayta D, Rejas J, Arumí D, Cañadas A, Lizarraga I.

Med Clin (Barc). 2014 Apr 8. pii: S0025-7753(14)00160-2. doi: 10.1016/j.medcli.2013.10.032. [Epub ahead of print] Spanish.

PMID:
24725856
[PubMed - as supplied by publisher]
5.

Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people >65 years of age: A post hoc analysis of data from the SOFIA study.

Wagg A, Darekar A, Arumi D, Khullar V, Oelke M.

Neurourol Urodyn. 2014 Apr 3. doi: 10.1002/nau.22603. [Epub ahead of print]

PMID:
24706493
[PubMed - as supplied by publisher]
6.

The effect of hyperactive bladder severity on healthcare utilization and labor productivity.

Angulo JC, Brenes FJ, Ochayta D, Lizarraga I, Arumí D, Trillo S, Rejas J.

Actas Urol Esp. 2014 May;38(4):249-56. doi: 10.1016/j.acuro.2013.11.002. Epub 2014 Jan 23. English, Spanish.

PMID:
24462234
[PubMed - in process]
7.

Therapeutic benefit in patients switching tolterodine to other novel antimuscarinic agents.

Sánchez-Ballester F, Miranda P, Lizarraga I, Rejas J, Arumi D.

Actas Urol Esp. 2014 Apr;38(3):156-63. doi: 10.1016/j.acuro.2013.07.008. Epub 2013 Oct 8. English, Spanish.

PMID:
24119382
[PubMed - in process]
8.

Effects of drug cessation after flexible-dose fesoterodine in patients with overactive bladder.

Khullar V, Cardozo L, Kelleher CJ, Hall T, Ryan J, Ebel Bitoun C, Darekar A, Arumi D, Wagg A.

BJU Int. 2013 Oct;112(6):820-9. doi: 10.1111/bju.12006. Epub 2013 Mar 7.

PMID:
23465055
[PubMed - indexed for MEDLINE]
9.

Predicting self-perceived antimuscarinic therapy effectiveness on overactive bladder symptoms using the Overactive Bladder 8-Question Awareness Tool.

Villacampa F, Ruiz MA, Errando C, Arlandis S, Arumí D, Lizarraga I, Rejas J.

Int Urogynecol J. 2013 Apr;24(4):573-81. doi: 10.1007/s00192-012-1921-x. Epub 2012 Oct 31.

PMID:
23111865
[PubMed - indexed for MEDLINE]
10.

Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study.

Castro-Diaz D, Miranda P, Sanchez-Ballester F, Lizarraga I, Arumí D, Rejas J.

BMC Urol. 2012 Jul 26;12:19. doi: 10.1186/1471-2490-12-19.

PMID:
22834707
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Quality of life in patients with overactive bladder: validation and psychometric properties of the Spanish Overactive Bladder Questionnaire-short Form.

Arlandis S, Ruiz MA, Errando C, Villacampa F, Arumí D, Lizarraga I, Rejas J.

Clin Drug Investig. 2012 Aug 1;32(8):523-32. doi: 10.2165/11633760-000000000-00000.

PMID:
22741748
[PubMed - indexed for MEDLINE]
12.

Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model.

Arlandis-Guzman S, Errando-Smet C, Trocio J, Arumi D, Rejas J.

BMC Urol. 2011 May 20;11:9. doi: 10.1186/1471-2490-11-9.

PMID:
21599928
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

[Assessment of reasons for overactive bladder treatment change].

Castro D, Miranda P, Sánchez-Ballester F, Arumi D, Lizarraga I, Ebel C; grupo de estudio Impacta.

Actas Urol Esp. 2011 Feb;35(2):73-9. doi: 10.1016/j.acuro.2010.11.011. Spanish.

PMID:
21296454
[PubMed - indexed for MEDLINE]
14.

[Prevalence of urinary incontinence and hyperactive bladder in the Spanish population: results of the EPICC study].

Martínez Agulló E, Ruiz Cerdá JL, Gómez Pérez L, Ramírez Backhaus M, Delgado Oliva F, Rebollo P, González-Segura Alsina D, Arumi D; Grupo de Estudio Cooperativo EPICC.

Actas Urol Esp. 2009 Feb;33(2):159-66. Spanish.

PMID:
19418840
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk